![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Springe zu: 2017
Anzahl der Publikationen: 2
2017
Grebely, Jason; Dalgard, Olav; Cunningham, Evan B.; Hajarizadeh, Behzad; Foster, Graham R.; Bruggmann, Philip; Conway, Brian; Backmund, Markus; Robaeys, Geert; Swan, Tracy; Amin, Janaki; Marks, Philippa S.; Quiene, Sophie; Applegate, Tanya L.; Weltman, Martin; Shaw, David; Dunlop, Adrian; Hellard, Margaret; Bruneau, Julie; Midgard, Havard; Bourgeois, Stefan; Stähelin, Cornelia und Dore, Gregory J.
(2017):
Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.
In: International Journal of Drug Policy, Bd. 47: S. 177-186
Cunningham, Evan B.; Hajarizadeh, Behzad; Dalgard, Olav; Amin, Janaki; Hellard, Margaret; Foster, Graham R.; Bruggmann, Philip; Conway, Brian; Backmund, Markus; Robaeys, Geert; Swan, Tracy; Marks, Philippa S.; Quiene, Sophie; Applegate, Tanya L.; Weltman, Martin; Shaw, David; Dunlop, Adrian; Bruneau, Julie; Midgard, Havard; Bourgeois, Stefan; Thurnheer, Maria Christine; Dore, Gregory J. und Grebely, Jason
(2017):
Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study.
In: BMC infectious Diseases
17:420
[PDF, 646kB]